Lexitas, Ocusun enroll first patient in pilot study of topical eye drop for age-related cataracts

Lexitas Pharma Services and Ocusun have announced enrollment of the first patient in a pilot study evaluating ZOC2017217, an investigational topical eye drop being developed as a potential non-surgical treatment for age-related cataracts.¹

The multicenter, randomized, double-masked, placebo-controlled study is designed to support an upcoming pivotal phase 3 trial and will assess the efficacy and safety of ZOC2017217 in participants with age-related cataracts (NCT07395986).¹

Cataract remains one of the most common causes of vision loss worldwide. According to the World Health Organization, more than 94 million people globally are affected, and in the US, cataract treatment accounts for an estimated $3.4 billion to $3.6 billion in annual Medicare spending.¹ Surgery is currently the only approved treatment option, a gap that has drawn increasing pipeline attention this year, from Harrow's phase 3 program for post-surgical inflammation to earlier-stage pharmacologic approaches aimed at the lens itself.^2,3

A pharmacologic approach to a surgical problem

ZOC2017217 is derived from lanosterol, a naturally occurring sterol that has been studied for its potential to interfere with the protein misfolding and aggregation underlying cataract formation. In preclinical studies, the therapy improved antioxidant activity and reduced lens opacity, according to the companies. Early clinical findings suggest the drop may also improve visual function and vision-related quality of life in patients with age-related cataract.¹

"The enrollment of our first patient marks an important milestone for the ZOC2017217 program, building on encouraging data from our exploratory study in China, where 50.0% to 86.4% of participants achieved a visual acuity of 20/40 or better 12 to 24 weeks post-treatment," said Terrence Li, chief medical officer and chief operating officer of Ocusun. "ZOC2017217 indicates a potential alternative treatment approach that could reshape the landscape of cataract care."

Lanosterol's role in cataract biology has been debated in the literature; earlier reports questioning the reproducibility of lanosterol's lens-clearing effect have coexisted with continued interest in the sterol as a starting point for pharmacologic intervention, underscoring why controlled, adequately powered trials—rather than exploratory data alone—will be needed to settle the question.⁴ ZOC2017217 is not the only pharmacologic candidate under investigation for age-related cataracts; a topical EDTA-based formulation reported positive subgroup results from a phase 1/2 study earlier this year, with its lead investigator noting that no FDA-approved pharmacological therapy for the condition currently exists.⁵

"Addressing visual function decline at the pre-surgical stage is a critical frontier in ophthalmic care," said Bacharach, medical director of North Bay Eye Associates and an investigator in the trial. "ZOC2017217 offers a first-of-its-kind pharmacological approach to managing cataract progression. I anticipate that this innovative therapy will significantly expand our clinical toolkit and fundamentally advance how we protect patient vision globally."

Jeanne Hecht, CEO of Lexitas Pharma Services, said the CRO is positioned to help generate the clinical evidence Ocusun needs as the program advances. "Cataracts remain one of the leading causes of vision impairment worldwide, and the development of a potential non-surgical treatment represents an exciting opportunity to advance patient care," Hecht said. "We are proud to support Ocusun in generating the clinical evidence needed to assess the potential of this innovative therapy and help inform the program's continued development."

What comes next

The pilot study is the latest in a string of first-patient-enrolled announcements this year across the anterior and posterior segment pipeline, joining trials such as Oculis' LEOPARD study of OCS-01 for cystoid macular edema and REGENXBIO's NAAVIGATE trial for diabetic retinopathy.^6,7 If the pilot data support advancement, Ocusun and Lexitas plan to move ZOC2017217 into a pivotal phase 3 program. For now, the study adds to a small but growing list of pharmacologic candidates attempting to intervene earlier in the cataract disease course, potentially delaying or reducing the eventual need for surgery.

References:

1. Lexitas Pharma Services and Ocusun Announce First Patient Enrolled in Pilot Study of ZOC2017217 for Age-Related Cataract. PRNewswire. July 14, 2026.

2. Harrow receives FDA IND clearance for phase 3 trial of TRIESENCE after cataract surgery. Ophthalmology Times. https://www.ophthalmologytimes.com/view/harrow-receives-fda-ind-clearance-for-phase-3-trial-of-triesence-after-cataract-surgery

3. Midyear cataract check-in: What 2026 has brought to the OR and beyond. Ophthalmology Times. https://www.ophthalmologytimes.com/view/midyear-cataract-check-in-2026

4. Focus on molecular mechanisms underlying cataract development. Ophthalmology Times. https://www.ophthalmologytimes.com/view/focus-on-molecular-mechanisms-underlying-cataract-development

5. Efficacy of novel eye drop to reverse cataracts after phase 1/2 study. Ophthalmology Times. https://www.ophthalmologytimes.com/view/efficacy-of-novel-eye-drop-to-reverse-cataracts-after-phase-1-2-study

6. Oculis enrolls first patient in LEOPARD trial of OSC-01 eye drops for treatment of CME. Ophthalmology Times. https://www.ophthalmologytimes.com/view/oculis-enrolls-first-patient-in-leopard-trial-of-osc-01-eye-drops-for-treatment-of-cme

7. REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy. Ophthalmology Times. https://www.ophthalmologytimes.com/view/regenxbio-doses-first-patient-in-naavigate-phase-2b-3-sura-vec-trial-for-diabetic-retinopathy